Skip to content

MDMA research published in 2019

71 studies whose primary subject is MDMA were published in 2019, down from 82 in 2018. Newest first. Back to the MDMA overview

Studies

MDMA-related deaths in Australia 2000 to 2018.

International Journal of Drug Policy December 19, 2019 A. Roxburgh, Julia Lappin 43 citations

BACKGROUND MDMA markets have undergone substantial changes internationally, with increasing manufacture of high purity MDMA recorded. This study examined trends in MDMA-related deaths in Australia, investigating characteristics, circumstances and toxicology of these deaths. METHODS Analysis of MDMA-related deaths in Australia between 2001 and 2018, extracted from the National Coronial...

Distinct neural mechanisms for the prosocial and rewarding properties of MDMA

Science Translational Medicine December 11, 2019 Boris D. Heifets, Juliana S Salgado, Madison Taylor et al. 119 citations

-fenfluramine, a selective serotonin-releasing compound. By dissociating the mechanisms of MDMA's prosocial effects from its addictive properties, we provide evidence for a conserved neuronal pathway, which can be leveraged to develop novel therapeutics with limited abuse liability.

The Acute Toxic and Neurotoxic Effects of 3,4-methylenedioxymethamphetamine are More Pronounced in Adolescent than Adult Mice

Behavioural Brain Research December 3, 2019 N. Chitre, M. Bagwell, Kevin S. Murnane

3,4-methylenedioxymethamphetamine (MDMA) recently achieved breakthrough status from the Food and Drug Administration (FDA) for post-traumatic stress disorder (PTSD). However, evidence indicates that exposure to toxic doses of 3,4-methylenedioxymethamphetamine (MDMA) can lead to long-lasting dysregulation of brain monoaminergic neurotransmitters, primarily from studies conducted in young adult...

MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings.

Cardiovascular toxicology December 2019 Alessandro Bonsignore, Rosario Barranco, Anna Morando et al.

3,4-Methylenedioxymethamphetamine (MDMA), more commonly known as "ecstasy," is a semi-synthetic entactogenic phenylethylamine. In recent years it has gained popularity as a recreational drug whose use has registered an upward trend especially among adolescents and young adults. Despite its unwarranted reputation of being a "safe" drug, the actual scientific data denote that it actually leaves a...

DOI: 10.1007/s12012-019-09526-9 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Cardio-toxicity MDMA-Related Deaths Myocardial damage

Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects

Neuropsychopharmacology November 16, 2019 Friederike Holze, Patrick Vizeli, Felix Müller et al. 250 citations

Abstract Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and d -amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and d -amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three...

Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization

Psychopharmacology November 15, 2019 Michael D. Berquist, Sebastian Leth-Petersen, Jesper L. Kristensen et al.

There is a renewed interest in the use of 3,4-methylenedioxymethamphetamine (MDMA) for treating psychiatric conditions. Although MDMA has entered phase II clinical trials and shows promise as an adjunct treatment, there is an extensive literature detailing the potential neurotoxicity and adverse neurobehavioral effects associated with MDMA use. Previous research indicates that the adverse...

Of mice and men on MDMA: a translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine ('Ecstasy').

Brain Research November 14, 2019 María A. Aguilar, María P García-Pardo, A. Parrott

MDMA (3,4-methylendioxymethamphetamine), also known as Ecstasy, is a stimulant drug recreationally used by young adults usually in dance clubs and raves. Acute MDMA administration increases serotonin, dopamine and noradrenaline by reversing the action of the monoamine transporters. In this work, we review the studies carried out over the last 30 years on the neuropsychobiological effects of...

Johns Hopkins Opens Research Center on Psychedelics

Psychiatric News October 28, 2019 Nick Zagorski 1 citation

A total of $17 million in private donations to the Hopkins center is expected to provide five years of operational funding for the center’s researchers and staff. The center will also train graduate students. With the aid of $17 million in private funds, Johns Hopkins University has launched a center to explore the potential of psychedelic compounds such as psilocybin (magic mushrooms) and...

No Influence of Dopamine System Gene Variations on Acute Effects of MDMA

Frontiers in Psychiatry October 24, 2019 Patrick Vizeli, Matthias E. Liechti 9 citations

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a recreational substance also investigated as medication for posttraumatic stress disorder. Dopamine (DA) system stimulation likely contributes to the acute mood effects of amphetamines, including MDMA. Genetic variants, such as single-nucleotide polymorphisms (SNPs), and polymorphic regions of the DA system genes may in part explain...

Locomotor sensitization in male Sprague-Dawley rats following repeated concurrent treatment with 4-methylmethcathinone and 3,4-methylenedioxymethamphetamine

Behavioural Pharmacology October 1, 2019 Trent A. Bullock, Michael D. Berquist, Lisa E Baker

Recreational abuse of illicit synthetic cathinones is an ongoing public health concern. Recent studies indicate that the methcathinone derivative 4-methylmethcathinone (4-MMC) produces behavioral and neurochemical effects similar to the entactogen 3,4-methylenedioxymethamphetamine (MDMA). Whereas polysubstance abuse is common, most preclinical studies of drug abuse liability only evaluate the...

Extinction training following cocaine or MDMA self-administration produces discrete changes in D2-like and mGlu5 receptor density in the rat brain.

Pharmacological Reports October 2019 Małgorzata Frankowska, Joanna Miszkiel, Lucyna Pomierny-Chamioło et al.

Several studies strongly support the role of the dopamine D2-like and glutamate mGlu5 receptors in psychostimulant reward and relapse. The present study employed cocaine or MDMA self-administration with yoked-triad procedure in rats to explore whether extinction training affects the drug-seeking behavior and the D2-like and mGlu5 receptor Bmax and Kd values in several regions of the animal...

DOI: 10.1016/j.pharep.2019.05.001 (opens in new tab) Full text (opens in new tab) Cocaine self-administration Dopamine d2-like receptor Extinction training Glutamate mglu5 receptor +2

Second and third year medical students’ self-reported alcohol and substance use, smoking habits and academic performance at a South African medical school

Health SA Gesondheid September 18, 2019 Annelize Vorster, Anthonie M. Gerber, Lynette J. van der Merwe et al. 21 citations

Background: Health professional students frequently use alcohol and narcotics. The potential impact on academic performance and professional behaviour is concerning.Aim: This study aimed to determine self-reported use of alcohol, illicit substances (e.g. cannabis, lysergic acid diethylamide [LSD], magic mushroom, cocaine, crack, ecstasy, methamphetamine and heroin), prescription medication and...

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Frontiers in Psychiatry September 12, 2019 Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski et al. 172 citations

Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for...

DOI: 10.3389/fpsyt.2019.00650 (opens in new tab) MDMA Paroxetine Sertraline Psychotherapist

Ecstasy induced acute systolic heart failure and Non-Ischemic Cardiomyopathy in a young female: a rare case report and literature review

Journal of Community Hospital Internal Medicine Perspectives September 6, 2019 Paritosh Kafle, Binav Shrestha, Amrendra Mandal et al.

Ecstasy or 3,4-methylenedioxymethamphetamine (MDMA) is an illicit recreational drug. Effects include euphoria, increased sensory awareness, and central stimulation. Although various arrhythmias, as well as dilated cardiomyopathy, have been previously noted to occur with chronic use, cardiac toxicities are seldom reported in an acute setting. Herein, we present a 28-year-old female patient with...

DOI: 10.1080/20009666.2019.1650593 (opens in new tab) Full text (opens in new tab) Ecstasy Non-st elevation mi Heart failure Non-ischemic cardiomyopathy +1

Effects of MDMA on attention to positive social cues and pleasantness of affective touch.

Neuropsychopharmacology September 2019 Anya K. Bershad, Leah M. Mayo, Kathryne Van Hedger et al.

The psychostimulant drug ±3,4-methylenedioxymethamphetamine (MDMA) reportedly produces distinctive feelings of empathy and closeness with others. MDMA increases social behavior in animal models and has shown promise in psychiatric disorders, such as autism spectrum disorder (ASD) and post-traumatic stress disorder (PTSD). How it produces these prosocial effects is not known. This behavioral and...

Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice.

Journal of Psychopharmacology September 2019 Sonia Abad, Carla Ramon-Duaso, Raúl López‐arnau et al.

3,4-Methylenedioxymethamphetamine (MDMA) is still one of the most consumed drugs by adolescents. Its abuse is related with cognitive impairment, which seems due to maladaptive plasticity and neural stress. In turn, new hypotheses suggest that Alzheimer's disease (AD) may be promoted by neural stressors. To test if there is an increase in vulnerability to AD after chronic MDMA consumption, we...

Sexual Ecstasy Scale: Conceptualizations and measurement

International Journal of Transpersonal Studies September 1, 2019

This article describes the development of the Sexual Ecstasy Scale, an instrument designed to measure the specific features that emerge when sexual arousal is the trigger for an ecstatic experience. Drawing from descriptions of features of sexual ecstasy in the phenomenological literature, the authors generated an initial survey of 31 items. In Study 1, the survey was completed by a wide...

'Never drop without your significant other, cause that way lies ruin': The boundary work of couples who use MDMA together.

International Journal of Drug Policy September 1, 2019 Katie Anderson, Paula Reavey, Zoë Boden 10 citations

MDMA has a variety of pro-social effects, such as increased friendliness and heightened empathy, yet there is a distinct lack of research examining how these effects might intertwine with a romantic relationship. This article seeks to compensate for this absence and explore heterosexual couples' use of MDMA through the lens of the boundaries they construct around these experiences. Three couple...

Motives for Classical and Novel Psychoactive Substances Use in Psychedelic Polydrug Users

Contemporary Drug Problems September 1, 2019 Hannes Kettner, Natasha L. Mason, Kim P. C. Kuypers 50 citations

Novel psychoactive substances (NPS) are compounds designed to mimic the effects of existing recreational drugs (classical psychoactive substances [CPS]), while eluding established legal frameworks. Little is known about their effects and potential harms, rendering the increasing number of NPS a challenge to policy makers and researchers alike. Quantitative studies on the motives underlying NPS...

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology September 1, 2019 Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al. 364 citations Retracted

Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Six randomized, double-blind, controlled clinical trials at five study sites were conducted...

DOI: 10.1007/s00213-019-05249-5 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Psychotherapy Posttraumatic stress disorder MDMA Alongside Therapy Active MDMA +7